SUBSCRIBE
SUBSCRIBE

Synexa Life Sciences

Synexa Life Sciences is a biomarker and bioanalytical lab CRO, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays.

With a team of over 200 staff across three global laboratory locations; Manchester, Turku (Finland) and Cape Town, we provide innovative solutions to support our customers to achieve their clinical milestones.

Our main areas of expertise include biomarker identification and development, large and small molecule clinical bioanalysis, (soluble) biomarker analysis (utilising MSD, LC-MS/MS, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry, ELISpot and Fluorospot) and genomic services to support clinical trials and translational studies.

We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis.

NEWS
Pictured: Facade of Moderna's building in Massachusetts
RSV
FDA Committee Calls For More Research After Moderna’s RSV Vaccine Safety Issues
Following news of RSV lower respiratory tract infections in infants immunized with Moderna’s investigational RNA vaccines, FDA advisors said the trial investigators should continue the study, while keeping an eye out for further safety signals.
December 13, 2024
 · 
3 min read
 · 
Tristan Manalac
Profit and Money Concept, Financial and Business Graph
Drug pricing
Drug Price Watchdog Calls Out Five Pharmas for Unjustified Price Hikes
The Institute for Clinical and Economic Review flagged five drugs whose prices were raised in 2023 with no evidence to support it. Meanwhile, the makers of these drugs have been reporting double-digit sales growth for many of these products.
December 13, 2024
 · 
3 min read
 · 
Annalee Armstrong
Set of crumpled lumps of different paper isolated on yellow background. Gritty dusty dotted effect, vector elements with jagged edges, old notebook sheets.
Cancer
Cancer Pipelines Shrink as Incyte, iTeos Cut Candidates Following Disappointing Data
Incyte is abandoning its ALK2 blocker zilurgisertib, which it was trialing for myelofibrosis-associated anemia, while iTeos will deprioritize the development of inupadenant after it failed to meet the biotech’s clinical bar in a Phase II study of metastatic non-small cell lung cancer.
December 13, 2024
 · 
2 min read
 · 
Tristan Manalac
Human liver organ and pills. World hepatitis day. National liver health awareness month. Liver transplantation, donation background. Save patient life in hospital with liver transplant
Postmarket research
Intercept’s Troubled Drug Ocaliva Linked to ‘Serious Liver Injury’: FDA
Ocaliva recently failed to secure the FDA’s traditional approval for primary biliary cholangitis due to safety concerns.
December 13, 2024
 · 
2 min read
 · 
Tristan Manalac
cutting off a row of people into pieces
Layoffs
Editas Axes 60% of Staff, Sickle Cell Therapy After Failing to Find Partner
The company had said in October said that it was looking to license out its ex vivo editor renizgamglogene autogedtemcel to focus its resources on its in vivo platform.
December 13, 2024
 · 
2 min read
 · 
Tristan Manalac
Novo Nordisk advertising flags and logo on facade
Regulatory
Novo Nordisk Snags Kidney Disease Expansion for Ozempic in Europe
The EMA approved a kidney disease–related label expansion for the blockbuster GLP-1 drug after a study showed reduced risk of death by 20%.
December 12, 2024
 · 
1 min read
 · 
Kate Goodwin
New York City, NY, USA - August 22, 2022: Pfizer world headquarters in New York City, USA. Pfizer Inc. is an American multinational pharmaceutical and biotechnology corporation.
Phase III
Pfizer’s Ibrance Improves Survival in New Breast Cancer Indication
Pfizer, facing increasing pressure from Novartis, is touting a Phase III win for Ibrance as the first clinical evidence supporting the CDK4/6 inhibitor class’ use in patients with a specific type of breast cancer.
December 12, 2024
 · 
1 min read
 · 
Annalee Armstrong
Illustration of DNA abstract molecule
Career Advice
The Right Fit: What BMS, Intellia Look for in Cell and Gene Therapy Talent
When hiring job candidates to work on cell and gene therapies, companies look for more than just technical skills. Talent acquisition executives from Bristol Myers Squibb and Intellia Therapeutics offer an inside look at what they want in an employee.
December 12, 2024
 · 
5 min read
 · 
Angela Gabriel
Contemporary art collage of hand holding an arrow showing fall. Modern design. Copy space.
Cardiovascular disease
Keros Suspends Two Arms of Hypertension Study After Reports of Pericardial Effusion
Keros’ stock plummeted more than 70% premarket Thursday and Truist Securities analysts predict it will remain under pressure until the safety concerns for cibotercept are resolved.
December 12, 2024
 · 
2 min read
 · 
Tristan Manalac
Load More
Visit website
Email Us
IN THE PRESS
Press Releases
Waters Sets a New Benchmark for Robustness and Sensitivity for High-Throughput Labs with the Xevo TQ Absolute XR Mass Spectrometer
June 2, 2025
 · 
4 min read
BioMidwest
Inotiv, Inc. Announces New Site Openings and Expansions Supporting Additional Capacity and Service Offerings
December 8, 2022
 · 
4 min read
Business
Parexel Announces Strategic Collaboration with Synexa Life Sciences and Drawbridge Health for COVID-19 Clinical Serology Testing Solution
November 2, 2020
 · 
4 min read
JOBS